Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors
作者:Rakesh K. Tiwari、Alex Brown、Neda Sadeghiani、Amir Nasrolahi Shirazi、Jared Bolton、Amanda Tse、Gennady Verkhivker、Keykavous Parang、Gongqin Sun
DOI:10.1002/cmdc.201600387
日期:2017.1.5
Derivatives of the tyrosine kinase inhibitor dasatinib were synthesized by esterification with 25 carboxylic acids, including amino acids and fatty acids, thereby extending the drug to interact with more diverse sites and to improve specificity. The dasatinib–l‐arginine derivative (Das‐R, 7) was found to be the most potent of the inhibitors tested, with IC50 values of 4.4, <0.25, and <0.45 nm against
酪氨酸激酶抑制剂dasatinib的衍生物是通过与25种羧酸(包括氨基酸和脂肪酸)进行酯化反应合成的,从而使该药物能够与更多位点相互作用并提高特异性。发现达沙替尼-1-精氨酸衍生物(Das-R,7)是最有效的抑制剂,对Csk,Src和Abl激酶的IC 50值为4.4,<0.25和<0.45 n m,分别。在我们的研究中获得的最高选择性比率,91.4了Csk / Src的,属于化合物18(DAS-C 10用IC)50的3.2μ值米为了Csk 35 N进行比较米对于Src。此外,许多化合物对Src的选择性高于对Abl的选择性。化合物15(Das-谷氨酸)和13(Das-半胱氨酸)显示出最大的增益(10.2和10.3 Abl / Src IC 50比)。DAS-R(IC 50 = 2.06μ米)是显著比母体达沙替尼更有效(IC 50 = 26.3μ米)对Panc-1细胞,而两种化合物显示出IC 50